CoviVac
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre,[1] which is an institute of the Russian Academy of Sciences.[2] It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[1] It has not yet gone through a phase III clinical trial as of early March 2021.[2]
Usage[edit]
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit).[1]
Authorization[edit]
Full authorization
Emergency authorization |
On 20 February 2021, President Vladimir Putin announced that the vaccine was approved.[1]
References[edit]
- ^ a b c d Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 13 March 2021.
- ^ a b Abbany Z (9 March 2021). "Two more Russian vaccines: What we do and don't know". Deutsche Welle. Retrieved 13 March 2021.
External links[edit]
 |
Scholia has a profile for CoviVac (Q105597762). |
.svg){kind=small}
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |